Litcius/Paper detail

Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade

Ying Zhang, Raghava N. Sriramaneni, Paul A. Clark, Justin C. Jagodinsky, Mingzhou Ye, Won Jong Jin, Yuyuan Wang, Amber M. Bates, Caroline P. Kerr, Trаng Lе, Raad H. Allawi, Xiuxiu Wang, Ruosen Xie, Thomas C. Havighurst, Ishan Chakravarty, Alexander L. Rakhmilevich, Kathleen A. O’Leary, Linda A. Schuler, Paul M. Sondel, KyungMann Kim, Shaoqin Gong, Zachary S. Morris

2022Nature Communications78 citationsDOIOpen Access PDF

Abstract

Radiation therapy (RT) activates an in situ vaccine effect when combined with immune checkpoint blockade (ICB), yet this effect may be limited because RT does not fully optimize tumor antigen presentation or fully overcome suppressive mechanisms in the tumor-immune microenvironment. To overcome this, we develop a multifunctional nanoparticle composed of polylysine, iron oxide, and CpG (PIC) to increase tumor antigen presentation, increase the ratio of M1:M2 tumor-associated macrophages, and enhance stimulation of a type I interferon response in conjunction with RT. In syngeneic immunologically "cold" murine tumor models, the combination of RT, PIC, and ICB significantly improves tumor response and overall survival resulting in cure of many mice and consistent activation of tumor-specific immune memory. Combining RT with PIC to elicit a robust in situ vaccine effect presents a simple and readily translatable strategy to potentiate adaptive anti-tumor immunity and augment response to ICB or potentially other immunotherapies.

Topics & Concepts

Immune checkpointBlockadeImmune systemCancer researchImmunotherapyTumor microenvironmentAntigen presentationAntigenCombination therapyImmunologyMedicineT cellPharmacologyReceptorInternal medicineCancer Immunotherapy and BiomarkersNanoplatforms for cancer theranosticsImmunotherapy and Immune Responses
Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade | Litcius